MedTrace Logo

Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer

NCT03484195 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-19

No results posted yet for this study

Summary

To evaluate the efficacy and safety of neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) in the patients with locally advanced colon cancer.

Conditions

  • Colonic Neoplasms
  • Drug Therapy

Interventions

DRUG

FOLFOXIRI

Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Jingdong Zhang · Cancer Hospital of China Medical University, Department of Medical Oncology, Liaoning Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03484195 on ClinicalTrials.gov